Literature DB >> 33662039

Radon-220 diffusion from 224Ra-labeled calcium carbonate microparticles: Some implications for radiotherapeutic use.

Elisa Napoli1,2,3, Tina B Bønsdorff1, Ida Sofie Jorstad1, Øyvind S Bruland2,4, Roy H Larsen1, Sara Westrøm1.   

Abstract

Alpha-particle emitting radionuclides continue to be the subject of medical research because of their high energy and short range of action that facilitate effective cancer therapies. Radium-224 (224Ra) is one such candidate that has been considered for use in combating micrometastatic disease. In our prior studies, a suspension of 224Ra-labeled calcium carbonate (CaCO3) microparticles was designed as a local therapy for disseminated cancers in the peritoneal cavity. The progenies of 224Ra, of which radon-220 (220Rn) is the first, together contribute three of the four alpha particles in the decay chain. The proximity of the progenies to the delivery site at the time of decay of the 224Ra-CaCO3 microparticles can impact its therapeutic efficacy. In this study, we show that the diffusion of 220Rn was reduced in labeled CaCO3 suspensions as compared with cationic 224Ra solutions, both in air and liquid volumes. Furthermore, free-floating lead-212 (212Pb), which is generated from released 220Rn, had the potential to be re-adsorbed onto CaCO3 microparticles. Under conditions mimicking an in vivo environment, more than 70% of the 212Pb was adsorbed onto the CaCO3 at microparticle concentrations above 1 mg/mL. Further, the diffusion of 220Rn seemed to occur whether the microparticles were labeled by the surface adsorption of 224Ra or if the 224Ra was incorporated into the bulk of the microparticles. The therapeutic benefit of differently labeled 224Ra-CaCO3 microparticles after intraperitoneal administration was similar when examined in mice bearing intraperitoneal ovarian cancer xenografts. In conclusion, both the release of 220Rn and re-adsorption of 212Pb are features that have implications for the radiotherapeutic use of 224Ra-labeled CaCO3 microparticles. The release of 220Rn through diffusion may extend the effective range of alpha-particle dose deposition, and the re-adsorption of the longer lived 212Pb onto the CaCO3 microparticles may enhance the retention of this nuclide in the peritoneal cavity.

Entities:  

Year:  2021        PMID: 33662039      PMCID: PMC7932545          DOI: 10.1371/journal.pone.0248133

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  22 in total

1.  A 212Pb generator based on a 228Th source.

Authors:  S Hassfjell
Journal:  Appl Radiat Isot       Date:  2001-10       Impact factor: 1.513

2.  Diffusing alpha-emitters radiation therapy: approximate modeling of the macroscopic alpha particle dose of a point source.

Authors:  Lior Arazi
Journal:  Phys Med Biol       Date:  2020-01-13       Impact factor: 3.609

3.  Calcium Carbonate Microparticles as Carriers of 224Ra: Impact of Specific Activity in Mice with Intraperitoneal Ovarian Cancer.

Authors:  Ruth Gong Li; Elisa Napoli; Ida Sofie Jorstad; Tina Bjørnlund Bønsdorff; Asta Juzeniene; Øyvind Sverre Bruland; Roy Hartvig Larsen; Sara Westrøm
Journal:  Curr Radiopharm       Date:  2021

4.  Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters.

Authors:  L Arazi; T Cooks; M Schmidt; Y Keisari; I Kelson
Journal:  Phys Med Biol       Date:  2007-08-01       Impact factor: 3.609

5.  A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.

Authors:  I Resche; J F Chatal; A Pecking; P Ell; G Duchesne; R Rubens; I Fogelman; S Houston; A Fauser; M Fischer; D Wilkins
Journal:  Eur J Cancer       Date:  1997-09       Impact factor: 9.162

6.  Matrix polyelectrolyte microcapsules: new system for macromolecule encapsulation.

Authors:  Dmitry V Volodkin; Alexander I Petrov; Michelle Prevot; Gleb B Sukhorukov
Journal:  Langmuir       Date:  2004-04-13       Impact factor: 3.882

7.  Initial Safety and Tumor Control Results From a "First-in-Human" Multicenter Prospective Trial Evaluating a Novel Alpha-Emitting Radionuclide for the Treatment of Locally Advanced Recurrent Squamous Cell Carcinomas of the Skin and Head and Neck.

Authors:  A Popovtzer; E Rosenfeld; A Mizrachi; S R Bellia; R Ben-Hur; G Feliciani; A Sarnelli; L Arazi; L Deutsch; I Kelson; Y Keisari
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-11-20       Impact factor: 7.038

Review 8.  Radiopharmaceutical therapy in cancer: clinical advances and challenges.

Authors:  George Sgouros; Lisa Bodei; Michael R McDevitt; Jessie R Nedrow
Journal:  Nat Rev Drug Discov       Date:  2020-07-29       Impact factor: 84.694

9.  Ra-224 labeling of calcium carbonate microparticles for internal α-therapy: Preparation, stability, and biodistribution in mice.

Authors:  Sara Westrøm; Marion Malenge; Ida Sofie Jorstad; Elisa Napoli; Øyvind S Bruland; Tina B Bønsdorff; Roy H Larsen
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-12       Impact factor: 1.921

View more
  2 in total

1.  Improved Formulation of 224Ra-Labeled Calcium Carbonate Microparticles by Surface Layer Encapsulation and Addition of EDTMP.

Authors:  Ruth Gong Li; Kim Lindland; Sandra Karen Tonstad; Tina Bjørnlund Bønsdorff; Asta Juzeniene; Sara Westrøm; Roy Hartvig Larsen
Journal:  Pharmaceutics       Date:  2021-04-29       Impact factor: 6.321

2.  A Novel Single-Step-Labeled 212Pb-CaCO3 Microparticle for Internal Alpha Therapy: Preparation, Stability, and Preclinical Data from Mice.

Authors:  Ruth Gong Li; Kim Lindland; Tina Bjørnlund Bønsdorff; Sara Westrøm; Roy Hartvig Larsen
Journal:  Materials (Basel)       Date:  2021-11-23       Impact factor: 3.623

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.